Avidity Biosciences Inc [RNA] stock prices are down -2.59% to $46.29 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RNA shares have gain 28.87% over the last week, with a monthly amount glided 47.09%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Bernstein started tracking the stock with Outperform rating on June 24, 2025, and set its price target to $50. On June 17, 2025, Wolfe Research initiated with a Outperform rating and assigned a price target of $55 on the stock. Raymond James started tracking the stock assigning a Strong Buy rating and suggested a price target of $65 on June 11, 2025. Citigroup initiated its recommendation with a Buy and recommended $70 as its price target on March 13, 2025. BMO Capital Markets started tracking with a Outperform rating for this stock on March 12, 2025, and assigned it a price target of $72. In a note dated March 07, 2025, Scotiabank initiated an Sector Outperform rating and provided a target price of $70 on this stock.
The stock price of Avidity Biosciences Inc [RNA] has been fluctuating between $21.51 and $56.00 over the past year. Currently, Wall Street analysts expect the stock to reach $70 within the next 12 months. Avidity Biosciences Inc [NASDAQ: RNA] shares were valued at $46.29 at the most recent close of the market. An investor can expect a potential return of 51.22% based on the average RNA price forecast.
Analyzing the RNA fundamentals
The Avidity Biosciences Inc [NASDAQ:RNA] reported sales of 10.73M for trailing twelve months, representing a surge of 88.12%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -48.53%, Pretax Profit Margin comes in at -41.36%, and Net Profit Margin reading is -41.36%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.27 and Total Capital is -0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Avidity Biosciences Inc [NASDAQ:RNA]’s Current Ratio is 9.26. Also, the Quick Ratio is 9.26, while the Cash Ratio stands at 3.0. Considering the valuation of this stock, the price to sales ratio is 555.02, the price to book ratio is 4.69.
Transactions by insiders
Recent insider trading involved Mosbrooker Eric, Chief Commercial Officer, that happened on Aug 06 ’25 when 0.13 million shares were sold. Director, WILSON TROY EDWARD completed a deal on Aug 06 ’25 to sell 65554.0 shares. Meanwhile, Director WILSON TROY EDWARD sold 29500.0 shares on Aug 06 ’25.
